Single agent talacotuzumab demonstrates limited efficacy but considerable toxicity in elderly high-risk MDS or AML patients failing hypomethylating agents

Treatment of MDS

(2019) Uwe Platzbecker   BLOOD

Monoclonal Antibody Therapies for Hematological Malignancies: Not Just Lineage-Specific Targets

(2018) Carlos Cuesta-Mateos et al.   Frontiers in Immunology

Therapeutic Antibodies for Myeloid Neoplasms—Current Developments and Future Directions

(2018) Christian M. Schürch   Frontiers in Oncology

CD123 target validation and preclinical evaluation of ADCC activity of anti-CD123 antibody CSL362 in combination with NKs from AML patients in remission

(2017) L H Xie et al.   Blood Cancer Journal

Recommendations for myeloid-derived suppressor cell nomenclature and characterization standards

(2016) Vincenzo Bronte et al.   Nature Communications

Treatment of Higher-Risk Myelodysplastic Syndromes After Failure of Hypomethylating Agents

(2015) Rami S. Komrokji   Clinical Lymphoma Myeloma & Leukemia

Targeting of acute myeloid leukemia in vitro and in vivo with an anti-CD123 mAb engineered for optimal ADCC

(2014) S J Busfield et al.   LEUKEMIA

Monoclonal Antibody-Mediated Targeting of CD123, IL-3 Receptor α Chain, Eliminates Human Acute Myeloid Leukemic Stem Cells

(2009) Liqing Jin et al.   Cell Stem Cell